Horizon Space Acquisition II (HSPT) agreed to merge with SL Bio, which is developing cellular and gene therapies for cancer treatment.
The combined entity will be listed on the Nasdaq, and shareholders of Horizon Space Acquisition and SL Bio will get shares in the newly formed company.
The transaction was approved by both boards and is expected to close late this year, the companies said Monday in a statement.
The new company will be led by SL Bio Chief Executive Officer William Wang.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.